M Mahler

Summary

Publications

  1. ncbi Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases
    Michael Mahler
    INOVA Diagnostics, Inc San Diego, CA 32131 1638, USA
    Autoimmun Rev 11:642-5. 2012
  2. ncbi Autoantibodies to the Rpp25 component of the Th/To complex are the most common antibodies in patients with systemic sclerosis without antibodies detectable by widely available commercial tests
    Michael Mahler
    From INOVA Diagnostics Inc, San Diego, California, USA the Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kita Kyushu, Japan Division of Rheumatology and Clinical Immunology, Department of Medicine, and Pathology, Immunology and Laboratory Medicine, and the Department of Oral Biology, University of Florida, Gainesville, Florida, USA Department of Medicine, McGill University the Division of Rheumatology and Lady Davis Institute, Jewish General Hospital, Montreal, Quebec the Department of Medicine, University of Calgary, Calgary, Alberta, Canada M Mahler, PhD, INOVA Diagnostics Inc M Satoh, MD, PhD, Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, and Division of Rheumatology and Clinical Immunology, Department of Medicine, and Pathology, Immunology and Laboratory Medicine, University of Florida M Hudson, MD, Department of Medicine, McGill University, Division of Rheumatology and Lady Davis Institute, Jewish General Hospital M Baron, MD, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital J Y F Chan E K L Chan
    J Rheumatol 41:1334-43. 2014
  3. pmc Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies
    Lucile Musset
    Department of Immunology, Université Pierre et Marie Curie AP HP Pitié Salpêtrière Hospital, Paris, France
    J Immunol Res 2014:405956. 2014
  4. pmc Clinical phenotypes of patients with anti-DFS70/LEDGF antibodies in a routine ANA referral cohort
    Makoto Miyara
    Department of Immunology, AP HP, Pitie Salpetriere Hospital, Paris, France
    Clin Dev Immunol 2013:703759. 2013
  5. ncbi PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease
    Michael Mahler
    INOVA Diagnostics, Inc, San Diego, CA, United States Electronic address
    Clin Chim Acta 424:267-73. 2013
  6. pmc The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases
    Michael Mahler
    INOVA Diagnostics, Inc, 9900 Old Grove Road, San Diego, CA 32131 1638, USA
    Clin Dev Immunol 2012:494356. 2012
  7. doi Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases
    Michael Mahler
    Department of Research, INOVA Diagnostics Inc, San Diego, California, USA
    J Rheumatol 39:2104-10. 2012
  8. doi Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome
    Michael Mahler
    INOVA Diagnostics, Inc, San Diego, CA 32131 1638, USA
    Autoimmun Rev 12:313-7. 2012
  9. doi The clinical significance of autoantibodies to the proliferating cell nuclear antigen (PCNA)
    Michael Mahler
    INOVA Diagnostics, Inc San Diego, CA 32131 1638, USA
    Autoimmun Rev 11:771-5. 2012
  10. doi Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies
    M Mahler
    INOVA Diagnostics, Inc, San Diego, CA 32131 1638, USA
    Clin Chim Acta 413:719-26. 2012

Detail Information

Publications19

  1. ncbi Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases
    Michael Mahler
    INOVA Diagnostics, Inc San Diego, CA 32131 1638, USA
    Autoimmun Rev 11:642-5. 2012
    ....
  2. ncbi Autoantibodies to the Rpp25 component of the Th/To complex are the most common antibodies in patients with systemic sclerosis without antibodies detectable by widely available commercial tests
    Michael Mahler
    From INOVA Diagnostics Inc, San Diego, California, USA the Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kita Kyushu, Japan Division of Rheumatology and Clinical Immunology, Department of Medicine, and Pathology, Immunology and Laboratory Medicine, and the Department of Oral Biology, University of Florida, Gainesville, Florida, USA Department of Medicine, McGill University the Division of Rheumatology and Lady Davis Institute, Jewish General Hospital, Montreal, Quebec the Department of Medicine, University of Calgary, Calgary, Alberta, Canada M Mahler, PhD, INOVA Diagnostics Inc M Satoh, MD, PhD, Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, and Division of Rheumatology and Clinical Immunology, Department of Medicine, and Pathology, Immunology and Laboratory Medicine, University of Florida M Hudson, MD, Department of Medicine, McGill University, Division of Rheumatology and Lady Davis Institute, Jewish General Hospital M Baron, MD, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital J Y F Chan E K L Chan
    J Rheumatol 41:1334-43. 2014
    ..Ribonuclease P protein subunit p25, (Rpp25) is an autoantigenic component of the Th/To complex. The contribution of anti-Th/To and anti-Rpp25 antibodies to ANA positivity in patients with SSc remains unknown...
  3. pmc Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies
    Lucile Musset
    Department of Immunology, Université Pierre et Marie Curie AP HP Pitié Salpêtrière Hospital, Paris, France
    J Immunol Res 2014:405956. 2014
    ..Testing various controls showed high specificity (99.3%). Anti-HMGCR antibodies are not always associated with the use of statin and appear to be the exclusive autoantibody specificity in patients with statin associated myopathies. ..
  4. pmc Clinical phenotypes of patients with anti-DFS70/LEDGF antibodies in a routine ANA referral cohort
    Makoto Miyara
    Department of Immunology, AP HP, Pitie Salpetriere Hospital, Paris, France
    Clin Dev Immunol 2013:703759. 2013
    ..To analyze the clinical value of anti-DFS70 antibodies in a cohort of patients undergoing routine antinuclear antibodies (ANAs) testing...
  5. ncbi PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease
    Michael Mahler
    INOVA Diagnostics, Inc, San Diego, CA, United States Electronic address
    Clin Chim Acta 424:267-73. 2013
    ..We determined if PR3-ANCA is a biomarker that differentiates ulcerative colitis (UC) from Crohn's disease (CrD)...
  6. pmc The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases
    Michael Mahler
    INOVA Diagnostics, Inc, 9900 Old Grove Road, San Diego, CA 32131 1638, USA
    Clin Dev Immunol 2012:494356. 2012
    ..This immunoadsorption method has the potential to overcome a significant limitation of the ANA HEp-2 assay. The present paper summarizes the current knowledge about anti-DFS70 antibodies and their clinical impact on ANA testing...
  7. doi Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases
    Michael Mahler
    Department of Research, INOVA Diagnostics Inc, San Diego, California, USA
    J Rheumatol 39:2104-10. 2012
    ....
  8. doi Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome
    Michael Mahler
    INOVA Diagnostics, Inc, San Diego, CA 32131 1638, USA
    Autoimmun Rev 12:313-7. 2012
    ..Moreover, we present a suggested guideline for future studies to better understand and verify the clinical utility of anti-β(2)GP1-D1 antibodies...
  9. doi The clinical significance of autoantibodies to the proliferating cell nuclear antigen (PCNA)
    Michael Mahler
    INOVA Diagnostics, Inc San Diego, CA 32131 1638, USA
    Autoimmun Rev 11:771-5. 2012
    ....
  10. doi Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies
    M Mahler
    INOVA Diagnostics, Inc, San Diego, CA 32131 1638, USA
    Clin Chim Acta 413:719-26. 2012
    ..We evaluated novel chemiluminescence assays (CIAs) for PR3- and MPO-ANCA detection and investigated their utility for disease activity monitoring...
  11. doi Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope
    M Mahler
    Development and Production, Dr Fooke Laboratorien, Mainstrasse 85, 41469 Neuss, Germany
    Rheumatol Int 32:691-8. 2012
    ..Although an association between anti-C22 reactivity and SLEDAI score was observed in one center, measurement of anti-C22 autoantibodies is likely not appropriate for measuring global disease activity...
  12. ncbi Sm peptides in differentiation of autoimmune diseases
    Michael Mahler
    INOVA Diagnostics Inc, San Diego, California, USA
    Adv Clin Chem 54:109-28. 2011
    ..Additionally, a meta-analysis focused on recent data analyzes the prevalence of anti-Sm antibodies in SLE...
  13. ncbi Performance evaluation of a novel chemiluminescence assay for detection of anti-GBM antibodies: an international multicenter study
    Michael Mahler
    INOVA Diagnostics, Inc San Diego, CA, USA
    Nephrol Dial Transplant 27:243-52. 2012
    ..The objective of our study was to carefully analyze the performance characteristics of a novel anti-glomerular basement membrane (GBM) chemiluminescence immunoassay (CIA)...
  14. doi Novel diagnostic and clinical aspects of anti-PCNA antibodies detected by novel detection methods
    M Mahler
    Dr Fooke Laboratorien, Neuss, Germany
    Lupus 19:1527-33. 2010
    ..The specific association of anti-PCNA antibodies with systemic lupus erythematosus was not confirmed in our study...
  15. pmc Improved serological differentiation between systemic lupus erythematosus and mixed connective tissue disease by use of an SmD3 peptide-based immunoassay
    M Mahler
    Dr Fooke Laboratorien GmbH, Mainstr 85, 41469 Neuss, Germany
    Clin Diagn Lab Immunol 12:107-13. 2005
    ..Finally, we conclude that the recently identified SmD peptide containing a symmetrical dimethylarginine at position 112 of D3 represents a promising tool for the detection of a highly specific subpopulation of anti-Sm antibodies...
  16. doi Latest update on the Ro/SS-A autoantibody system
    J Schulte-Pelkum
    Dr Fooke Laboratorien GmbH, Neuss, Germany
    Autoimmun Rev 8:632-7. 2009
    ..It was concluded that Ro60 (SS-A) and Ro52 represent two distinct autoantibody systems and that separate detection is desirable in a clinical diagnostic setting...
  17. ncbi Serological and clinical characterization of anti-dsDNA and anti-PM/Scl double-positive patients
    M Mahler
    Dr Fooke Laboratorien GmbH, Neuss, Germany
    Ann N Y Acad Sci 1109:311-21. 2007
    ..Clinically, anti-dsDNA(+)/anti-PM/Scl(+) patients may define a small subgroup of SLE patients with additional features of systemic sclerosis...
  18. ncbi Development and evaluation of a rapid assay for the diagnosis of immunoglobulin E-mediated type I allergies
    R Lucassen
    Dr Fooke Laboratorien GmbH, Neuss, Germany
    J Investig Allergol Clin Immunol 18:223-4. 2008